Advertisement
IDEAYA Biosciences Q4 Results Misses Estimates
(RTTNews) - IDEAYA Biosciences, Inc. (IDYA), a precision medicine oncology company, announced net loss of $32.64 million or $0.52 per share, wider than $23.07 million or $0.50 per share in the prior-year quarter.
Collaboration revenues for the quarter declined to $3.92 million from $4.02 million in the same quarter last year.
On average, ten analysts polled by Thomson Reuters expected the company to report a loss of $0.47 per share on revenues of $8.84 million for the quarter. Analysts' estimates typically exclude special items.
For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com
read more
IDEAYA Biosciences Says FDA Clears IND For Pol Theta Helicase Development Candidate GSK101
Oncology company IDEAYA Biosciences, Inc. (IDYA) announced Monday the clearance of an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) for initiation of a GSK-sponsored Phase 1/2 clinical trial to evaluate GSK101 (IDE705) for the treatment of patients having tumors with BRCA or other homologous recombination (HR) mutations or homologous recombination deficiency (HRD).
RTTNews
|
Pred 733 dňami
IDEAYA Biosciences Appoints Darrin Beaupre As Chief Medical Officer
Oncology company IDEAYA Biosciences, Inc. (IDYA) announced that Darrin Beaupre has joined the company as its Chief Medical Officer, effective November 21, 2022.
RTTNews
|
Pred 999 dňami
U.S. Dollar Drops After Powell's Speech
The U.S. dollar weakened against its major counterparts in the New York session on Friday, as Federal Reserve Chair Jerome Powell hinted at a potential rate cut next month.
RTTNews
|
Pred 17 h 25 min
TSX Hits New Record High As Stocks Rally On Fed Rate Cut Hopes
The Canadian market is up firmly in positive territory a little past noon on Friday, with stocks from across several sectors moving higher on strong buying support amid rising hopes of an interest rate cut by the Federal Reserve in September.
RTTNews
|
Pred 22 h 55 min
Powell Says Outlook, Shifting Balance Of Risks 'May Warrant' Lower Rates
Federal Reserve Chair Jerome Powell delivered a highly-anticipated speech before the Jackson Hole Economic Symposium on Friday, although he touched only briefly on the outlook for monetary policy. "With policy in restrictive territory, the baseline outlook and the shifting balance of risks may warrant adjusting our policy stance," Powell said.
RTTNews
|
Pred 1 dňom
Bay Street Likely To Open On Mixed Note; Powell's Speech Eyed
Canadian shares are likely to open on a somewhat mixed note Friday morning with investors awaiting Fed Chair Jerome Powell's speech at Jackson Hole. Lower commodity prices may weigh a bit early on in the session.
RTTNews
|
Pred 1 dňom
Sensex, Nifty Snap Six-day Winning Streak On Tariff Concerns
Indian shares fell sharply on Friday after a Trump administration official called India the 'Maharaja' of tariffs and ramped up his criticism over the trade ahead of an expected tariff increase on August 27.
RTTNews
|
Pred 1 dňom
FTSE 100 Down Slightly; Standard Chartered Shares Up Sharply
U.K. stocks are turning in a mixed performance in cautious trade on Friday, amid a lack of fresh triggers. Investors are awaiting Fed Chair Jerome Powell's speech later in the day at the Jackson Hole Symposium, for clues about U.S. central bank's interest rate move next month.
RTTNews
|
Pred 1 dňom
